Search

CN-116672460-B - Polyvanadate-based compound capable of resisting obesity and reducing obesity-related inflammation, and preparation and application thereof

CN116672460BCN 116672460 BCN116672460 BCN 116672460BCN-116672460-B

Abstract

The invention discloses a poly-vanadate complex with anti-obesity and obesity-related inflammation reducing functions, and a preparation method and application thereof. The invention mixes glucosamine hexavanadate with functional food additives to prepare the poly-vanadate composite. The polyvanadate complex is capable of significantly reducing the weight of mice, particularly in reducing adipose tissue accumulation and inflammation at the adipose tissue site. The poly-vanadate complex can reduce the accumulation of macrophages in adipose tissue of mice, enhance iNKT cell function of HFD mice, and reduce the number of pro-inflammatory factors, thereby reducing systemic adipose tissue inflammation of HFD mice.

Inventors

  • CHEN KUN
  • LIU SHENGQIU
  • YIN PANCHAO

Assignees

  • 华南理工大学

Dates

Publication Date
20260508
Application Date
20220222

Claims (9)

  1. 1. A poly-vanadate complex for resisting obesity and reducing obesity-related inflammation is characterized by being prepared by compounding glucosamine hexavanadate and a functional food additive according to a mass ratio of 1:0.5-1:0.8; the glucosamine hexavanadate is tetradecanoic acid modified glucosamine hexavanadate, and the molecular formula of the tetradecanoic acid modified glucosamine hexavanadate is (C 6 H 15 NO 5 ) 2 [V 6 O 13 {(OCH 2 ) 3 CCH 2 OOC(CH 2 ) 12 CH 3 } 2 ]; The functional food additive is at least one of sorbitol, isomaltooligosaccharide and galacto-oligosaccharide.
  2. 2. A method of preparing a polyvanadate complex having anti-obesity and reduced inflammation associated with obesity as claimed in claim 1, comprising the steps of: (1) Performing cation exchange on tetrabutylammonium hexavanadate modified by tetradecanoic acid, and uniformly mixing with glucosamine to obtain glucosamine hexavanadate; (2) Uniformly mixing the glucosamine hexavanadate aqueous solution and the functional food additive aqueous solution, and dehydrating at low temperature to obtain the polyvanadate complex with the functions of resisting obesity and reducing obesity-related inflammation.
  3. 3. The method of claim 2, wherein the tetrabutylammonium hexavanadate salt modified by tetradecanoic acid in step (1) is an ionic compound having tetrabutylammonium as a cation and D-glucosamine as an anion of [V 6 O 13 {(OCH 2 ) 3 CCH 2 OOC(CH 2 ) 12 CH 3 } 2 ] 2- ; and wherein the glucosamine in step (1) is D-glucosamine.
  4. 4. The method for producing a polyvanadate complex having anti-obesity and reduced inflammation associated with obesity according to claim 2, the method is characterized in that the molar ratio of the tetrabutylammonium hexavanadate modified by the tetradecanoic acid to the glucosamine in the step (1) is 1:2.
  5. 5. The method of claim 2, wherein the cation exchange in step (1) is performed using a cation exchange resin.
  6. 6. The preparation method of the polyvanadate complex for resisting obesity and reducing obesity-related inflammation according to claim 2, wherein the mass concentration of the glucosamine hexavanadate aqueous solution in the step (2) is 10-15%, the mass concentration of the functional food additive aqueous solution is 5-12%, and the volume ratio of the glucosamine hexavanadate aqueous solution to the functional food additive aqueous solution is 1:1.
  7. 7. The method for preparing a poly-vanadate complex for preventing obesity and reducing inflammation associated with obesity according to claim 2, wherein the dehydration temperature in the step (2) is 30-50 ℃.
  8. 8. Use of a polyvanadate complex having anti-obesity and reduced inflammation associated with obesity according to claim 1 in the preparation of anti-obesity drugs and animal food.
  9. 9. Use of a poly-vanadate complex having anti-obesity and reduced inflammation associated with obesity according to claim 1 in the manufacture of an anti-obesity animal medical drug.

Description

Polyvanadate-based compound capable of resisting obesity and reducing obesity-related inflammation, and preparation and application thereof Technical Field The invention belongs to the field of animal medicine, and in particular relates to a poly-vanadate complex with functions of resisting obesity and reducing obesity-related inflammation, and a preparation method and application thereof. Background Pets play an important role in modern society, and the bad moods of many people can be effectively relieved by being in contact with the pets. Cats and dogs as pets often experience obesity due to diet transition caused by improper feeding by the breeder. Obesity can have a serious impact on the physical health of cats and dogs and the life of the breeder. Obesity can cause joint and skeletal dyskinesia in cats and dogs, and excessive body weight not only causes inconvenience in movement, but also can cause stress on bone joints, thereby causing problems such as disc displacement, arthritis, foot (paw) dysplasia and the like. The obesity problem of cats and dogs can also make it difficult to breathe, which is more pronounced during exercise. In addition, obesity can cause visceral lesions, endocrine dyscrasia and other problems of cats and dogs, and the visceral lesions and endocrine dyscrasia can cause serious threat to the life health of cats and dogs. Obesity is closely related to metabolic disorders, insulin resistance, especially inflammation, etc. For example, a key regulator of inflammatory cell function, receptor-acting serine/threonine protein kinase 1 (RIPK 1), is involved not only in inflammation, apoptosis and necrosis, but also at the gene level in the occurrence of obesity in mammals under inflammatory stimulation. Furthermore, a recent study has shown that patients under intensive care admitted to SARS-CoV-2 have a high probability of developing obesity. One of the characteristics of obesity is the accumulation of triglycerides and lipid droplets in the viscera, which at the same time increases the risk of developing type 2 diabetes in patients. In animals in an obese state, adipose tissue secretes a large amount of pro-inflammatory and anti-inflammatory cytokines, which not only causes systemic chronic inflammation in the body, but also exacerbates the chronic low-grade inflammation. In animals with transitional obesity, white fat cells are excessively expanded, thereby causing local tissue hypoxia and necrosis, and further causing various metabolic inflammations. Generally, the weight of the pet is controlled by the breeder by feeding a low calorie pet food with high protein, low carbon water, high fiber, and low fat. However, such pet foods are usually expensive, most of them belong to imported goods, and the official purchase channels are easy to cut off. Therefore, it is necessary to develop cost-effective food and pharmaceutical adjuvants for controlling the weight of cats and dogs. Disclosure of Invention To solve the drawbacks and disadvantages of the prior art, a primary object of the present invention is to provide a polyvanadate complex having anti-obesity and reduced inflammation associated with obesity. The poly-vanadate complex can remarkably reduce the weight and body fat of HFD mice (obese mice caused by high fat diet), reduce the adipose tissue inflammation, and improve the insulin resistance symptoms of the mice, thereby improving the metabolic disorder state of the mice. Another object of the present invention is to provide a method for preparing the above-mentioned poly vanadate complex for anti-obesity and reducing inflammation associated with obesity. The poly vanadate complex can be obtained by adopting a method of physically mixing the poly vanadate alkoxy derivative and the functional food additive. It is still another object of the present invention to provide the use of the above-mentioned polyvanadate complex for the preparation of medicaments and animal food for treating obesity and reducing obesity-related inflammation. The invention aims at realizing the following technical scheme: a poly-vanadate complex with anti-obesity and anti-obesity related inflammation reducing effects is prepared by compounding glucosamine hexavanadate and a functional food additive according to a mass ratio of 1:0.5-1:0.8; The glucosamine hexavanadate is para-trihydroxy ligand substituted tetradecanoic acid modified glucosamine hexavanadate, wherein the trihydroxy ligand is trimethylolethyl myristate, and the molecular formula of the tetradecanoic acid modified glucosamine hexavanadate is (C6H15NO5)2[V6O13{(OCH2)3CCH2OOC(CH2)12CH3}2],, and the molecular weight of the tetradecanoic acid modified glucosamine hexavanadate is 1562.97. The functional food additive is at least one of sorbitol, isomaltooligosaccharide and galacto-oligosaccharide. The preparation method of the poly-vanadate complex for resisting obesity and reducing obesity-related inflammation comprises the following steps of: (1